相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
Wei-Xiang Qi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
Wei-Xiang Qi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Wei-Xiang Qi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
Guru Sonpavde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
Philippe Rougier et al.
EUROPEAN JOURNAL OF CANCER (2013)
Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
Wei-Xiang Qi et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
Shanthi Sivendran et al.
CANCER TREATMENT REVIEWS (2012)
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer
Patricia A. Tang et al.
CLINICAL CANCER RESEARCH (2012)
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
H. J. Mackay et al.
GYNECOLOGIC ONCOLOGY (2012)
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2012)
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
Nicoletta Colombo et al.
GYNECOLOGIC ONCOLOGY (2012)
Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
Rodryg Ramlau et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
Fabio A. B. Schutz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
Walter H. Gotlieb et al.
LANCET ONCOLOGY (2012)
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiao Feng Hang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis
Vishal Ranpura et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura et al.
ACTA ONCOLOGICA (2010)
A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung
Natasha B. Leighl et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
Xiaolei Zhu et al.
ACTA ONCOLOGICA (2009)
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
Youjin Je et al.
LANCET ONCOLOGY (2009)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
Shenhong Wu et al.
LANCET ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Endothelial cells and VEGF in vascular development
L Coultas et al.
NATURE (2005)
Role of angiogenesis in cardiovascular disease - A critical appraisal
R Khurana et al.
CIRCULATION (2005)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Heterogeneity testing in meta-analysis of genome searches
E Zintzaras et al.
GENETIC EPIDEMIOLOGY (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
MJ Sweeting et al.
STATISTICS IN MEDICINE (2004)
Role of angiogenesis in tumor growth and metastasis
J Folkman
SEMINARS IN ONCOLOGY (2002)
分享论文
